Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF

Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF

Bibliographic Details
Main Authors: Gathe, Joseph, Arribas, Jose R., Van Lunzen, Jan, Garner, Will, Speck, Rebecca M., Bender, Randall, Shreay, Sanatan, Nguyen, Thai
Format: Online
Language:English
Published: Springer International Publishing 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575373/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575373/

Similar Items